Hasil Pencarian (14063)
Halaman 160 / 282JAK4D is a first-in-class thyrotropin-releasing hormone (TRH)-based compound.
Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
Janagliflozin is under investigation in clinical trial NCT03851432 (Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin).
The Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. The vaccine was created in collaboration with Johnson and Johnson (J&J), Janssen Pharma…
Deskripsi belum tersedia.
JHU-75528 C-11 is under investigation in clinical trial NCT03204305 (Brain Imaging of Cannabinoid Receptors).
JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.[L46686]
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.[A253997]
Deskripsi belum tersedia.
JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).
JNJ-27390467 is a potent, nonpeptide inhibitor of human mast cell tryptase.
JNJ-27548547 is under investigation in clinical trial NCT01705002 (Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.).
Deskripsi belum tersedia.
A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body mass in male rats and stimulates sexual behavior in female rats.
JNJ-37822681 has been used in trials studying the treatment of Schizophrenia.
JNJ-39220675 has been used in trials studying the treatment of Allergic Rhinitis.
JNJ-39393406 has been used in trials studying the treatment and basic science of DEPRESSION, Schizophrenia, Smoking Cessation, Cognition Disorders, and Alzheimer's Disease.
JNJ-39758979 is under investigation in clinical trial NCT01480388 (A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate).
JNJ-40346527 has been used in trials studying the treatment of Health and Arthritis, Rheumatoid.
JNJ-40411813 has been used in trials studying the treatment and basic science of Confusion, Schizophrenia, Perceptual Disorders, and Major Depressive Disorder.
JNJ-41443532 has been used in trials studying the basic science and treatment of Diabetes Mellitus, Type 2.
Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants).
JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma).
JNJ-55308942 is under investigation in clinical trial NCT05328297 (A Study of JNJ-55308942 in the Treatment of Bipolar Depression).
JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies).
A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
Deskripsi belum tersedia.
JPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and favourable…
First-in-class potent and selective inhibitor of the BRD4 signaling pathway.[A252967]
JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age…
An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]
JZP-386 is a deuterium-containing analog of sodium oxybate. Its safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.
Deskripsi belum tersedia.
K-134 has been used in trials studying the treatment of Intermittent Claudication.
Deskripsi belum tersedia.